Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer

被引:376
|
作者
Singer, PA
Cooper, DS
Daniels, GH
Ladenson, PW
Greenspan, FS
Levy, EG
Braverman, LE
Clark, OH
McDougall, IR
Ain, KV
Dorfman, SG
机构
[1] UNIV SO CALIF,SCH MED,DIV ENDOCRINOL DIABET & HYPERTENS,LOS ANGELES,CA
[2] JOHNS HOPKINS UNIV,SCH MED,DIV ENDOCRINOL,BALTIMORE,MD
[3] MT SINAI HOSP,DIV ENDOCRINOL,BALTIMORE,MD
[4] MASSACHUSETTS GEN HOSP,THYROID UNIT,BOSTON,MA 02114
[5] UNIV CALIF SAN FRANCISCO,SCH MED,DIV ENDOCRINOL,SAN FRANCISCO,CA
[6] UNIV MIAMI,SCH MED,DIV ENDOCRINOL,MIAMI,FL
[7] UNIV MASSACHUSETTS,SCH MED,DIV ENDOCRINOL,WORCESTER,MA
[8] UNIV CALIF SAN FRANCISCO,MT ZION MED CTR,SCH MED,DEPT SURG,SAN FRANCISCO,CA 94120
[9] STANFORD UNIV,MED CTR,SCH MED,DIV NUCL MED,STANFORD,CA 94305
[10] UNIV KENTUCKY,DIV ENDOCRINOL,LEXINGTON,KY
[11] ENDOCRINE ASSOCIATES DALLAS,DALLAS,TX
关键词
D O I
10.1001/archinte.156.19.2165
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A set of minimum clinical guidelines for use by primary care physicians in the evaluation and management of patients with thyroid nodules or thyroid cancer was developed by consensus by an Ii-member Standards of Care Committee (the authors of the article) of the American Thyroid Association, New York, NY. The participants were selected by the committee chairman and by the president of the American Thyroid Association based on their clinical experience. The committee members represented different geographic areas within the United States, to reflect different practice patterns. The guidelines were developed based on the expert opinion of the committee participants, as well as on previously published information. Each committee participant was initially assigned to write a section of the document and to submit it to the committee chairman, who revised and assembled the sections into a complete draft document, which was then circulated among all committee members for further revision. Several of the committee members further revised and refined the document, which was then submitted to the entire membership of the American Thyroid Association for written comments and suggestions, many of which were incorporated into a final draft document, which was reviewed and approved by the Executive Council of the American Thyroid Association.
引用
收藏
页码:2165 / 2172
页数:8
相关论文
共 50 条
  • [41] Conservative management of well-differentiated thyroid cancer
    Hassanain, Mazen
    Wexler, Marvin
    CANADIAN JOURNAL OF SURGERY, 2010, 53 (02) : 109 - 118
  • [42] Management of the Neck in Well-Differentiated Thyroid Cancer
    Panagiotis Asimakopoulos
    Ashok R. Shaha
    Iain J. Nixon
    Jatin P. Shah
    Gregory W. Randolph
    Peter Angelos
    Mark E. Zafereo
    Luiz P. Kowalski
    Dana M. Hartl
    Kerry D. Olsen
    Juan P. Rodrigo
    Vincent Vander Poorten
    Antti A. Mäkitie
    Alvaro Sanabria
    Carlos Suárez
    Miquel Quer
    Francisco J. Civantos
    K. Thomas Robbins
    Orlando Guntinas-Lichius
    Marc Hamoir
    Alessandra Rinaldo
    Alfio Ferlito
    Current Oncology Reports, 2021, 23
  • [43] Impact of previous thyroid autoimmune diseases on prognosis of patients with well-differentiated thyroid cancer
    Souza, SL
    da Assumpçao, LVM
    Ward, LS
    THYROID, 2003, 13 (05) : 491 - 495
  • [44] Well-differentiated carcinoma of the thyroid
    Boone, RT
    Fan, CY
    Hanna, EY
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2003, 36 (01) : 73 - +
  • [45] Well-differentiated thyroid carcinoma
    Segal, K
    Raveh, E
    Lubin, E
    Abraham, A
    Shvero, J
    Feinmesser, R
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1996, 17 (06) : 401 - 406
  • [46] Rapid thyroid nodule growth is not a marker for well-differentiated thyroid cancer
    Falch, Claudius
    Axt, Steffen
    Scuffi, Bettina
    Koenigsrainer, Alfred
    Kirschniak, Andreas
    Muller, Sven
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2015, 13
  • [47] Rapid thyroid nodule growth is not a marker for well-differentiated thyroid cancer
    Claudius Falch
    Steffen Axt
    Bettina Scuffi
    Alfred Koenigsrainer
    Andreas Kirschniak
    Sven Muller
    World Journal of Surgical Oncology, 13
  • [48] Radioiodine Treatment of Well-Differentiated Thyroid Cancer: Balancing Risks and Benefits
    Greenspan, Bennett S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18) : 1785 - +
  • [49] Biologic basis for the treatment of microscopic, occult well-differentiated thyroid cancer
    Furlan, JC
    Bedard, Y
    Rosen, LB
    SURGERY, 2001, 130 (06) : 1050 - 1054
  • [50] Quality of life with well-differentiated thyroid cancer: Treatment toxicities and their reduction
    Mendoza, A
    Shaffer, B
    Karakla, D
    Mason, ME
    Elkins, D
    Goffman, TE
    THYROID, 2004, 14 (02) : 133 - 140